With acquisition, vision and deep pockets, Kriya Therapeutics eyes new day for gene therapy
One of the acquired programs — coupling gene therapy with the generic smoking cessation drug Chantix to quell hyperactive neurons in epilepsy patients — could be ready for a clinical trial next year or 2024.
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Ron Leuty Source Type: news
More News: American Health | Brain | Chantix | Clinical Trials | Epilepsy | Eyes | Gene Therapy | Genetics | Health Management | Mergers and Aquisitions | Neurology | Smokers